Jia Y. Jin

12 Middle Wulumuqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma.

Clinical Impact of BTK Inhibitor Exposure in LymphGen-Defined MCD Diffuse Large B-Cell Lymphoma.

Journal: Hematological oncology

Published: June 04, 2026

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Journal: Blood cancer journal

Published: January 01, 2026

Genomic risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma.

Genomic risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma.

Journal: Blood research

Published: May 17, 2025

Direct and indirect measurement of liquid film thickness by common optical methods.

Direct and indirect measurement of liquid film thickness by common optical methods.

Journal: The Review of scientific instruments

Published: February 27, 2025

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.

PBVD regimen (pegylated liposomal doxorubicin, bleomycin, vincristine, dacarbazine) in classical Hodgkin lymphoma patients with cardiovascular risk factors: a retrospective study.

Journal: Leukemia & lymphoma

Published: January 05, 2025

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.

Journal: Blood cancer journal

Published: October 04, 2024

Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.

Chidamide plus R-GDP for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for autologous transplantation: A prospective, single-arm, phase II study.

Journal: Cancer medicine

Published: February 05, 2024

Analysis of Isokinetic Strength Test in Arthroscopic Meniscus Suture to Improve Knee Joint Strength and Function.

Analysis of Isokinetic Strength Test in Arthroscopic Meniscus Suture to Improve Knee Joint Strength and Function.

Journal: Alternative therapies in health and medicine

Published: June 29, 2023

High-purity isolation platelets by gradient centrifugation plus filtration.

High-purity isolation platelets by gradient centrifugation plus filtration.

Journal: International journal of laboratory hematology

Published: June 06, 2022

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.

Clinical Characteristics and Prognostic Factors in Primary Breast Diffuse Large B-Cell Lymphoma.

Journal: Mediterranean journal of hematology and infectious diseases

Published: May 07, 2022

Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.

Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era.

Journal: International journal of hematology

Published: January 27, 2022

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.

Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.

Journal: BMC cancer

Published: September 07, 2021

Showing 1-12 of 25

Last Updated: 09/26/2026